Definium Therapeutics (NASDAQ:DFTX) CFO Brandi Roberts Sells 3,013 Shares

Definium Therapeutics, Inc. (NASDAQ:DFTX) CFO Brandi Roberts sold 3,013 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $135,675.39. Following the completion of the transaction, the chief financial officer owned 209,487 shares of the company’s stock, valued at $9,433,199.61. The trade was a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Definium Therapeutics Stock Up 0.4%

Shares of NASDAQ:DFTX opened at $44.95 on Friday. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. The firm has a market cap of $4.48 billion, a price-to-earnings ratio of -18.05 and a beta of 2.37. The stock’s 50-day moving average price is $24.59 and its two-hundred day moving average price is $19.36. Definium Therapeutics, Inc. has a 12-month low of $6.40 and a 12-month high of $47.01.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23). On average, research analysts forecast that Definium Therapeutics, Inc. will post -2.29 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a report on Monday. Royal Bank Of Canada reiterated an “outperform” rating on shares of Definium Therapeutics in a report on Monday. Stifel Nicolaus set a $30.00 price target on Definium Therapeutics and gave the company a “buy” rating in a research report on Thursday, April 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Tuesday, April 21st. Finally, Needham & Company LLC lifted their price objective on Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $47.08.

Institutional Investors Weigh In On Definium Therapeutics

Several hedge funds have recently modified their holdings of DFTX. Commodore Capital LP boosted its holdings in Definium Therapeutics by 10.5% in the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after acquiring an additional 475,000 shares during the period. Vanguard Group Inc. raised its stake in shares of Definium Therapeutics by 11.0% during the third quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock valued at $23,732,000 after purchasing an additional 198,878 shares during the period. Rosalind Advisors Inc. lifted its position in shares of Definium Therapeutics by 78.6% during the third quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock worth $8,842,000 after purchasing an additional 330,000 shares in the last quarter. UBS Group AG boosted its stake in shares of Definium Therapeutics by 7.3% in the third quarter. UBS Group AG now owns 551,809 shares of the company’s stock valued at $6,506,000 after purchasing an additional 37,364 shares during the period. Finally, Orbimed Advisors LLC purchased a new position in shares of Definium Therapeutics in the third quarter valued at $4,337,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium said its Phase III depression program delivered positive results, a key catalyst that can support optimism about eventual approval and commercialization. Definium raises $805 million after positive Phase III depression data
• Positive Sentiment: The company closed an upsized public offering, raising $805 million, which strengthens its balance sheet and reduces near-term financing risk. Definium Therapeutics Announces Closing of $805 Million Upsized Public Offering
• Neutral Sentiment: Several insiders, including the CEO and CFO, sold shares at $45.03. Insider selling can sometimes pressure sentiment, but the transactions were relatively small compared with their remaining holdings. CEO insider filing
• Neutral Sentiment: Market commentary and analyst writeups also pointed to the stock’s sharp move higher after the Phase III news, reinforcing the view that investors are reacting to the clinical-data catalyst. Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 15.35%
• Negative Sentiment: Heavy insider selling from multiple executives may temper enthusiasm, as some investors could interpret it as a sign management views the stock as fully valued near recent highs.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.